Hypertrophic Cardiomyopathy (HCM)MAP HCMNCT07454135
Mechanisms of Atrial Pathoelectrophysiology in HCM
An observational study of Hypertrophic Cardiomyopathy (HCM) and Atrial Fibrillation (AF), run by Guy's and St Thomas' NHS Foundation Trust at 1 site in United Kingdom.
Trial summary
This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Hypertrophic Cardiomyopathy (HCM), Atrial Fibrillation (AF)
- How many people
- 40 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 26 May 2026to 30 Sep 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with hypertrophic cardiomyopathy and atrial fibrillation requiring atrial fibrillation ablation.
Who may be able to join
- Paroxysmal or persistent atrial fibrillation
- Diagnosis of hypertrophic cardiomyopathy
- Patient planning to proceed to atrial fibrillation ablation following clinical consultation
- Age 18-80 years
- Able and willing to provide written informed consent
- Able and willing to comply with study follow up requirements
Who cannot join
- Any clinical contra-indication to ablation
- Any disease limiting life expectancy to <1 year
- Potential participant currently pregnant or breast feeding
- Contraindication to MRI including renal dysfunction (eGFR<30ml/min)
- Unable to understand verbal or written explanations given in English
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site, 1 recruiting
- Recruiting
Guy's and St Thomas' NHS Foundation Trust
London
Magdalena Klis, 02071887188, magda.klis@kcl.ac.uk
About this study
This study aims to learn why atrial fibrillation (AF), a type of irregular heartbeat, happens more often and is harder to treat in people with hypertrophic cardiomyopathy (HCM). HCM is an inherited condition where the heart muscle is thicker than usual.
Researchers will study electrical signals from the heart and advanced heart imaging. By doing this, they hope to better understand how AF behaves in people with HCM and why treatments may not work as well for them.
The information from this study may help improve future treatments for people who have both HCM and AF.
- Keywords
- hypertrophic cardiomyopathy, atrial fibrillation
- Medical subject headings
- Cardiomyopathy, Hypertrophic, Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with HCM and AF | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in bipolar voltage, conduction velocity, refractory periods and conduction divergence of the atria in patients with HCM and AF compared to patients with AF and structurally normal hearts
Measured: At the time of the clinical ablation procedure
Secondary outcomes (2)
Correlatation between the bipolar voltage in the atria with directly measured left atrial pressure, extent of late gadolinium enhancement and ventricular extracellular volume .
Measured: At the time of clinical ablation procedure
Reduction in AF inducibility in silico models following simulated ablation
Measured: Based on measurements taken during the clinical ablation procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Mar 2026
- Study start26 May 2026
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hypertrophic Cardiomyopathy (HCM)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Sponsor type
- University, hospital or other
- Collaborators
- King's College London
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07454135
- Sponsor's protocol ID
- 339394
- Acronym
- MAP HCM
- Status last verified
- Mar 2026
- First submitted
- 2 Mar 2026
- Last updated
- 11 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No